| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486530 | EXELA PHARMA | Ganciclovir compositions and related methods |
Sep, 2034
(10 years from now) | |
Ganzyk-Rtu is owned by Exela Pharma.
Ganzyk-Rtu contains Ganciclovir.
Ganzyk-Rtu has a total of 1 drug patent out of which 0 drug patents have expired.
Ganzyk-Rtu was authorised for market use on 17 February, 2017.
Ganzyk-Rtu is available in solution;intravenous dosage forms.
The generics of Ganzyk-Rtu are possible to be released after 02 September, 2034.
Drugs and Companies using GANCICLOVIR ingredient
Market Authorisation Date: 17 February, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
GANZYK-RTU family patents
